Paper17538164
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
Curran D and 11 others. J Clin Oncol, 2007. Cited by 185 papers, by iCite.
Cite this record
ConductScience Library. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. Papers, record 17538164. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538164
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| Antineoplastic Agents | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| ErbB Receptors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Quality of Life | Major topic |
| Antibodies, Monoclonal, Humanized | |
| Cetuximab | |
| Health Status | |
| Humans | |
| Prognosis |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00700440 | Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy | Background |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17538157 | Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. | https://conductscience.org/library/papers/17538157 |
Source PubMed
Cited by93
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41825810 | Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial. | Int J Radiat Oncol Biol Phys | 2026 | https://conductscience.org/library/papers/41825810 | PubMed |
| 40214872 | Predictors of survival among head and neck cancer patients after radiotherapy based on health-related quality of life indices and symptoms-specific outcomes: a systematic review. | Qual Life Res | 2025 | https://conductscience.org/library/papers/40214872 | PubMed |
| 40162076 | The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/40162076 | PubMed |
| 39457986 | From Bench to Bedside: A Team's Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. | J Clin Med | 2024 | https://conductscience.org/library/papers/39457986 | PubMed |
| 39376987 | Improved quality of life in head and neck cancer patients treated with modern arc radiotherapy techniques - A prospective longitudinal analysis. | Front Oncol | 2024 | https://conductscience.org/library/papers/39376987 | PubMed |
| 39144266 | Radiation-induced skin injury in the head and neck region: pathogenesis, clinics, prevention, treatment considerations and proposal for management algorithm. | Rep Pract Oncol Radiother | 2024 | https://conductscience.org/library/papers/39144266 | PubMed |
| 38525491 | First Phase Development of a Patient-reported Outcome Measure for Midface Oncology. | Plast Reconstr Surg Glob Open | 2024 | https://conductscience.org/library/papers/38525491 | PubMed |
| 38436503 | Impact of Adjuvant Radiotherapy Setting on Quality-of-Life in Head and Neck Squamous Cell Carcinoma. | Laryngoscope | 2024 | https://conductscience.org/library/papers/38436503 | PubMed |
| 38193937 | Quality of life following treatment with intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. | Support Care Cancer | 2024 | https://conductscience.org/library/papers/38193937 | PubMed |
| 37992137 | Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study. | Med Oral Patol Oral Cir Bucal | 2024 | https://conductscience.org/library/papers/37992137 | PubMed |
| 36683928 | Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. | Natl J Maxillofac Surg | 2022 | https://conductscience.org/library/papers/36683928 | PubMed |
| 36001247 | Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2). | Int J Clin Oncol | 2022 | https://conductscience.org/library/papers/36001247 | PubMed |
| 35836484 | Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study. | Oncol Lett | 2022 | https://conductscience.org/library/papers/35836484 | PubMed |
| 35463348 | Quality of Life Analysis of HPV-Positive Oropharyngeal Cancer Patients in a Randomized Trial of Reduced-Dose Versus Standard Chemoradiotherapy: 5-Year Follow-Up. | Front Oncol | 2022 | https://conductscience.org/library/papers/35463348 | PubMed |
| 35343648 | Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin. | Cancer Med | 2022 | https://conductscience.org/library/papers/35343648 | PubMed |
| 35149773 | Quality of life score as a prognosticator for pharyngeal cancer patients treated with radiotherapy. | Sci Rep | 2022 | https://conductscience.org/library/papers/35149773 | PubMed |
| 34285948 | Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer. | Int J Part Ther | 2021 | https://conductscience.org/library/papers/34285948 | PubMed |
| 33289866 | Health-related quality of life and overall survival: a prospective study in patients with head and neck cancer treated with radiotherapy. | Qual Life Res | 2021 | https://conductscience.org/library/papers/33289866 | PubMed |
| 32936912 | Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. | Radiat Res | 2020 | https://conductscience.org/library/papers/32936912 | PubMed |
| 32920767 | Randomized Clinical Trial on Reduction of Radiotherapy Dose to the Elective Neck in Head and Neck Squamous Cell Carcinoma: Results on the Quality of Life. | Qual Life Res | 2021 | https://conductscience.org/library/papers/32920767 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538164
GET https://conductscience.org/api/papers/v1/17538164/cited_by?page=2